Conference Coverage

Biosimilars primer: What you need to know now


 

EXPERT ANALYSIS FROM 2015 ADVANCES IN IBD

References

The meeting was sponsored by the Crohn’s & Colitis Foundation of America. Dr. Rubin has financial and consulting relationships with AbbVie, Janssen, Takeda, and numerous other pharmaceutical companies. Dr. Feagan has numerous relationships with pharmaceutical companies, including Abbott, Janssen, Teva, and others. Dr. Hanauer has served on the board of AbbVie and has financial relationships with numerous other pharmaceutical manufacturers. Dr. Regueiro did not have any disclosures relevant to this story.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

This article was updated 1/6/16.

Pages

Recommended Reading

Portal venous blood yielded higher levels of circulating tumor cells
MDedge Internal Medicine
Increased prevalence of pancreatic cysts due to MRI improvements
MDedge Internal Medicine
EREFS value has diagnostic utility for eosinophilic esophagitis
MDedge Internal Medicine
Tocilizumab markedly increases rate of lower gastrointestinal perforation
MDedge Internal Medicine
Postop C. diff infection associated with presurgical antibiotics
MDedge Internal Medicine
AGA publishes microscopic colitis guideline
MDedge Internal Medicine
Anti-TNF therapy can continue for IBD patients with skin lesions
MDedge Internal Medicine
ELF the most effective mortality predictor for coinfected HIV, HCV patients
MDedge Internal Medicine
New antivirals, more screening could slash hepatitis C cases
MDedge Internal Medicine
FDA approves treatment for chemotherapy ODs, life-threatening toxicities
MDedge Internal Medicine